Literature DB >> 16186413

Association between peroxisome proliferator-activated receptor gamma haplotypes and the metabolic syndrome in French men and women.

Aline Meirhaeghe1, Dominique Cottel, Philippe Amouyel, Jean Dallongeville.   

Abstract

We assessed the association of four polymorphisms (promoter P3 -681C>G, P2 -689C>T, Pro12Ala, and 1431C>T) in peroxisome proliferator-activated receptor gamma (PPARgamma) with the metabolic syndrome risk in a large, French population study (n = 1,155). In this sample, 279 men and women presented with metabolic syndrome according to the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) criteria. When taken individually, none of the polymorphisms was significantly associated with the metabolic syndrome. Haplotype analyses, in contrast, revealed a significant enrichment of the GTGC haplotype frequency (corresponding to the P3 -681C>G, P2 -689C>T, Pro12Ala (C/G), and 1431C>T polymorphisms in this order) among those with metabolic syndrome compared with control subjects. Compared with the most common CCCC haplotype, the adjusted odds ratio (OR) (95% CI) of the metabolic syndrome for bearers of the GTGC haplotype was 2.37 (1.42-3.95; P = 0.002), 1.92 (1.00-3.72; P = 0.05), and 2.47 (1.09-5.62; P = 0.045) in the whole sample of men and women, respectively. Similar results were obtained when using another haplotype (GCCC, GTGT, CCCT, or GCCT) as a reference. Furthermore, when the GTGC haplotype frequency was tested alone (i.e., versus the frequency of the five other haplotypes together), the OR (95% CI) of the metabolic syndrome was 2.30 (1.05-5.00; P = 0.022). These data show that only the frequency of the GTGC haplotype was different between subjects with and without metabolic syndrome. Further analyses stratified on the 1431C>T single nucleotide polymorphism (SNP) indicated that the rare alleles of the P2 -689C>T and Pro12Ala SNPs were associated with an increased risk of the metabolic syndrome when combined to the 1431CC genotype. In conclusion, a specific haplotype of PPARgamma polymorphisms is associated with an increased risk of the metabolic syndrome in a French general population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186413     DOI: 10.2337/diabetes.54.10.3043

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  20 in total

1.  The challenges for molecular nutrition research 1: linking genotype to healthy nutrition.

Authors:  Christine M Williams; Jose M Ordovas; Dennis Lairon; John Hesketh; Georg Lietz; Mike Gibney; Ben van Ommen
Journal:  Genes Nutr       Date:  2008-07       Impact factor: 5.523

2.  Variation in PPARG is associated with longitudinal change in insulin resistance in Mexican Americans at risk for type 2 diabetes.

Authors:  Mary Helen Black; Jun Wu; Miwa Takayanagi; Nan Wang; Kent D Taylor; Talin Haritunians; Enrique Trigo; Jean M Lawrence; Richard M Watanabe; Thomas A Buchanan; Anny H Xiang
Journal:  J Clin Endocrinol Metab       Date:  2015-01-13       Impact factor: 5.958

3.  Proteomic analysis yields an unexpected trans-acting point in control of the human sympathochromaffin phenotype.

Authors:  Stéphane Chiron; Zhiyun Wei; Yuqing Chen; Kuixing Zhang; Gen Wen; Wolfgang H Fischer; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2011-05-06

4.  Polymorphisms of the peroxisome proliferator-activated receptor γ (PPARγ) gene are associated with osteoporosis.

Authors:  T Harsløf; C L Tofteng; L B Husted; M Nyegaard; A Børglum; M Carstens; L Stenkjær; K Brixen; P Eiken; J-E B Jensen; L Mosekilde; L Rejnmark; B L Langdahl
Journal:  Osteoporos Int       Date:  2010-11-23       Impact factor: 4.507

5.  Associations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population.

Authors:  Hassan Rooki; Monir-sadat Haerian; Pedram Azimzadeh; Reza Mirhafez; Mahmoud Ebrahimi; Gordon Ferns; Majid Ghayour-Mobarhan; Mohammad-Reza Zali
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

6.  PPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues.

Authors:  Valerio Costa; Maria Assunta Gallo; Francesca Letizia; Marianna Aprile; Amelia Casamassimi; Alfredo Ciccodicola
Journal:  PPAR Res       Date:  2010-09-08       Impact factor: 4.964

7.  Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease.

Authors:  Jean Dallongeville; Carlos Iribarren; Jean Ferrières; Liisa Lyon; Alun Evans; Alan S Go; Dominique Arveiler; Stephen P Fortmann; Pierre Ducimetière; Mark A Hlatky; Philippe Amouyel; Audrey Southwick; Thomas Quertermous; Aline Meirhaeghe
Journal:  PPAR Res       Date:  2009-12-01       Impact factor: 4.964

Review 8.  Genetics of metabolic syndrome.

Authors:  Tisha Joy; Piya Lahiry; Rebecca L Pollex; Robert A Hegele
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

Review 9.  PPAR gamma and human metabolic disease.

Authors:  Robert K Semple; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

10.  Screening of Peroxisome Proliferator-Activated Receptors (PPARs) α, γ and α Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population.

Authors:  Phee-Phee Chia; Sook-Ha Fan; Yee-How Say
Journal:  Ethn Dis       Date:  2015-11-05       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.